Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daniel Junius Insider Profile
4 Followers
Daniel Junius, Director at ImmunoGen, holds 98.46K shares in GlycoMimetics (Ticker: GLYC), holds 3.04K shares in Idexx Laboratories (Ticker: IDXX), holds 184.99K shares in ImmunoGen (Ticker: IMGN).
Profitable Transactions
18 out of 35 Profitable Transactions
Average Return
+6.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Daniel Junius holds in companies
Most Profitable Insider Trade
The most profitable trade made by Daniel Junius
Daniel Junius's Trading History
ImmunoGen
Mar 16, 2018
―
Informative Sell
300.25K
$5.78M
GlycoMimetics
Apr 02, 2024
Director
Uninformative Buy
15.63K
$180.67K
Vitae Pharma
―
―
―
―
Idexx Laboratories
Feb 01, 2024
Director
Uninformative Buy
7.29K
$1.50M
List of latest transactions for each holding click on a transaction to see Daniel Junius's performance on stock
You May Also Like
Daniel Junius insider profile FAQ
What is the percentage of profitable transactions made by Daniel Junius?
The percentage of profitable transactions made by Daniel Junius is 51%.
What is the average return per transaction made by Daniel Junius?
The average return per transaction made by Daniel Junius is 6.60%.
What stocks does Daniel Junius hold?
Daniel Junius holds: IMGN, GLYC, VTAE, IDXX stocks.
What was Daniel Junius’s latest transaction?
Daniel Junius latest transaction was an Uninformative Buy of $15.63K.
What was Daniel Junius's most profitable transaction?
Daniel Junius’s most profitable transaction was an Informative Buy of GLYC stock on December 21, 2016. The return on the trade was 168.10%.
What is Daniel Junius's role in ImmunoGen?
Daniel Junius's role in ImmunoGen is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.